• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶酶体酸性脂肪酶活性降低——在儿童非酒精性脂肪性肝病发病机制中的潜在作用

Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients.

作者信息

Selvakumar Praveen Kumar Conjeevaram, Kabbany Mohammad Nasser, Lopez Rocio, Tozzi Giulia, Alisi Anna, Alkhouri Naim, Nobili Valerio

机构信息

Department of Pediatric Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA.

Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, USA.

出版信息

Dig Liver Dis. 2016 Aug;48(8):909-13. doi: 10.1016/j.dld.2016.04.014. Epub 2016 Apr 29.

DOI:10.1016/j.dld.2016.04.014
PMID:27198736
Abstract

BACKGROUND

Within the spectrum of nonalcoholic fatty liver disease (NAFLD), recent evidence suggests that adult patients with nonalcoholic steatohepatitis (NASH) have significantly lower blood lysosomal acid lipase (LAL) activity than those with steatosis. This has not been studied in pediatric patients with NAFLD.

AIM

Investigate blood LAL activity in pediatric patients with NAFLD and assess its correlation with histological severity.

METHODS

We collected data on consecutive children with biopsy-proven NAFLD including demographics, anthropometrics, and routine laboratory tests. The histological features were graded according to the NAFLD activity scoring proposed by Kleiner et al. Blood LAL activity was measured prospectively using Lalistat 2.

RESULTS

A total of 168 children were included for analysis. Mean age was 12.6±8.5 years, 60.1% were males and 52.4% had NASH. Children with significant fibrosis (stage 2-3, n=64) had a significantly lower LAL activity compared to those with mild fibrosis (stage 0-1, n=104). There was no significant difference in LAL activity between children with NASH compared to those without NASH.

CONCLUSION

Reduced blood LAL activity correlates with severity of liver fibrosis in children with NAFLD indicating a potential role of reduced LAL activity in the pathogenesis of NAFLD-induced fibrosis.

摘要

背景

在非酒精性脂肪性肝病(NAFLD)范围内,最近的证据表明,患有非酒精性脂肪性肝炎(NASH)的成年患者血溶酶体酸性脂肪酶(LAL)活性明显低于患有脂肪变性的患者。尚未在患有NAFLD的儿科患者中进行此项研究。

目的

研究患有NAFLD的儿科患者的血LAL活性,并评估其与组织学严重程度的相关性。

方法

我们收集了经活检证实患有NAFLD的连续儿童的数据,包括人口统计学、人体测量学和常规实验室检查。根据Kleiner等人提出的NAFLD活动评分对组织学特征进行分级。使用Lalistat 2前瞻性测量血LAL活性。

结果

共有168名儿童纳入分析。平均年龄为12.6±8.5岁,60.1%为男性,52.4%患有NASH。与轻度纤维化(0-1期,n=104)的儿童相比,显著纤维化(2-3期,n=64)的儿童LAL活性显著降低。患有NASH的儿童与未患有NASH的儿童之间的LAL活性无显著差异。

结论

血LAL活性降低与患有NAFLD的儿童肝纤维化严重程度相关,表明LAL活性降低在NAFLD诱导的纤维化发病机制中具有潜在作用。

相似文献

1
Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients.溶酶体酸性脂肪酶活性降低——在儿童非酒精性脂肪性肝病发病机制中的潜在作用
Dig Liver Dis. 2016 Aug;48(8):909-13. doi: 10.1016/j.dld.2016.04.014. Epub 2016 Apr 29.
2
Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease.血液和血小板中溶酶体酸性脂肪酶活性降低与非酒精性脂肪性肝病相关。
Clin Transl Gastroenterol. 2020 Feb;11(2):e00116. doi: 10.14309/ctg.0000000000000116.
3
Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?溶酶体酸性脂肪酶活性降低:非酒精性脂肪性肝病临床连续谱中肝脏疾病严重程度的新标志物?
World J Gastroenterol. 2019 Aug 14;25(30):4172-4180. doi: 10.3748/wjg.v25.i30.4172.
4
Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease.血清溶酶体酸性脂肪酶活性降低与晚期肝病相关。
Int J Mol Sci. 2016 Feb 27;17(3):312. doi: 10.3390/ijms17030312.
5
A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease.溶酶体酸性脂肪酶活性相对缺乏是非酒精性脂肪性肝病的特征。
Int J Mol Sci. 2017 May 25;18(6):1134. doi: 10.3390/ijms18061134.
6
Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease.溶酶体酸性脂肪酶活性与非酒精性脂肪性肝病临床连续统中的肝纤维化。
Liver Int. 2019 Dec;39(12):2301-2308. doi: 10.1111/liv.14206. Epub 2019 Aug 21.
7
Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease.在非酒精性脂肪性肝病患者中,脾脏大小与溶酶体酸性脂肪酶活性呈负相关。
Intern Emerg Med. 2017 Dec;12(8):1159-1165. doi: 10.1007/s11739-017-1746-1. Epub 2017 Sep 12.
8
Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.非酒精性脂肪性肝病——组织学评分系统:一项大型队列单中心评估研究。
APMIS. 2017 Nov;125(11):962-973. doi: 10.1111/apm.12742.
9
Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease.成年非酒精性脂肪性肝病患者溶酶体酸性脂肪酶活性降低
EBioMedicine. 2015 May 22;2(7):750-4. doi: 10.1016/j.ebiom.2015.05.018. eCollection 2015 Jul.
10
Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.2 型糖尿病患者非酒精性脂肪性肝病的组织病理学分期:患病率及相关因素。
Liver Int. 2011 May;31(5):700-6. doi: 10.1111/j.1478-3231.2011.02482.x. Epub 2011 Feb 20.

引用本文的文献

1
Lanifibranor Reduces Inflammation and Improves Dyslipidemia in Lysosomal Acid Lipase-Deficient Mice.拉尼菲布诺可减轻溶酶体酸性脂肪酶缺陷小鼠的炎症并改善血脂异常。
Gastro Hep Adv. 2024 May 28;3(6):711-723. doi: 10.1016/j.gastha.2024.05.006. eCollection 2024.
2
Recent insights into lysosomal acid lipase deficiency.溶酶体酸性脂肪酶缺乏症的最新研究进展。
Trends Mol Med. 2023 Jun;29(6):425-438. doi: 10.1016/j.molmed.2023.03.001. Epub 2023 Apr 5.
3
Lysosomal Acid Lipase Deficiency: Genetics, Screening, and Preclinical Study.溶酶体酸性脂肪酶缺乏症:遗传学、筛查和临床前研究。
Int J Mol Sci. 2022 Dec 8;23(24):15549. doi: 10.3390/ijms232415549.
4
Lysosomal Acid Lipase Activity in Non-alcoholic Fatty Liver Disease as a Novel Diagnostic and Therapeutic Target: A Systematic Literature Review of Current Evidence and Future Directions.非酒精性脂肪性肝病中溶酶体酸性脂肪酶活性作为一种新型诊断和治疗靶点:当前证据及未来方向的系统文献综述
J Clin Exp Hepatol. 2022 Nov-Dec;12(6):1535-1546. doi: 10.1016/j.jceh.2022.04.011. Epub 2022 Apr 15.
5
Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?溶酶体酸性脂肪酶酶活性可用于隐源性肝硬化的临床随访吗?
Turk J Med Sci. 2022 Aug;52(4):1075-1084. doi: 10.55730/1300-0144.5410. Epub 2022 Aug 10.
6
Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions.非酒精性脂肪性肝病:关注新的生物标志物和生活方式干预。
Int J Mol Sci. 2021 Apr 9;22(8):3899. doi: 10.3390/ijms22083899.
7
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?肝内脂质堆积如何导致非酒精性脂肪性肝病的脂毒性?
Hepatol Int. 2021 Feb;15(1):21-35. doi: 10.1007/s12072-020-10121-2. Epub 2021 Feb 6.
8
Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms.小儿非酒精性脂肪肝疾病:营养起源与潜在分子机制。
Nutrients. 2020 Oct 16;12(10):3166. doi: 10.3390/nu12103166.
9
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B.非酒精性脂肪性肝病与慢性乙型肝炎并存的一种新的地方病
Microorganisms. 2020 Oct 4;8(10):1526. doi: 10.3390/microorganisms8101526.
10
Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?溶酶体酸性脂肪酶活性降低:非酒精性脂肪性肝病临床连续谱中肝脏疾病严重程度的新标志物?
World J Gastroenterol. 2019 Aug 14;25(30):4172-4180. doi: 10.3748/wjg.v25.i30.4172.